Literature DB >> 26751519

Let There Be Light: Gene and Cell Therapy for Blindness.

Deniz Dalkara1, Olivier Goureau1, Katia Marazova1, José-Alain Sahel1,2,3.   

Abstract

Retinal degenerative diseases are a leading cause of irreversible blindness. Retinal cell death is the main cause of vision loss in genetic disorders such as retinitis pigmentosa, Stargardt disease, and Leber congenital amaurosis, as well as in complex age-related diseases such as age-related macular degeneration. For these blinding conditions, gene and cell therapy approaches offer therapeutic intervention at various disease stages. The present review outlines advances in therapies for retinal degenerative disease, focusing on the progress and challenges in the development and clinical translation of gene and cell therapies. A significant body of preclinical evidence and initial clinical results pave the way for further development of these cutting edge treatments for patients with retinal degenerative disorders.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 26751519      PMCID: PMC4779297          DOI: 10.1089/hum.2015.147

Source DB:  PubMed          Journal:  Hum Gene Ther        ISSN: 1043-0342            Impact factor:   5.695


  131 in total

1.  High-efficiency transduction of the mouse retina by tyrosine-mutant AAV serotype vectors.

Authors:  Hilda Petrs-Silva; Astra Dinculescu; Qiuhong Li; Seok-Hong Min; Vince Chiodo; Ji-Jing Pang; Li Zhong; Sergei Zolotukhin; Arun Srivastava; Alfred S Lewin; William W Hauswirth
Journal:  Mol Ther       Date:  2008-12-16       Impact factor: 11.454

2.  Stem cells in age-related macular degeneration and Stargardt's macular dystrophy - Authors' reply.

Authors:  Steven D Schwartz; Eddy Anglade; Robert Lanza
Journal:  Lancet       Date:  2015-07-04       Impact factor: 79.321

3.  Mutations in the RPE65 gene in patients with autosomal recessive retinitis pigmentosa or leber congenital amaurosis.

Authors:  H Morimura; G A Fishman; S A Grover; A B Fulton; E L Berson; T P Dryja
Journal:  Proc Natl Acad Sci U S A       Date:  1998-03-17       Impact factor: 11.205

4.  Genomic DNA nanoparticles rescue rhodopsin-associated retinitis pigmentosa phenotype.

Authors:  Zongchao Han; Marcellus J Banworth; Rasha Makkia; Shannon M Conley; Muayyad R Al-Ubaidi; Mark J Cooper; Muna I Naash
Journal:  FASEB J       Date:  2015-02-24       Impact factor: 5.191

5.  Functional cone rescue by RdCVF protein in a dominant model of retinitis pigmentosa.

Authors:  Ying Yang; Saddek Mohand-Said; Aude Danan; Manuel Simonutti; Valérie Fontaine; Emmanuelle Clerin; Serge Picaud; Thierry Léveillard; José-Alain Sahel
Journal:  Mol Ther       Date:  2009-03-10       Impact factor: 11.454

6.  Inner limiting membrane barriers to AAV-mediated retinal transduction from the vitreous.

Authors:  Deniz Dalkara; Kathleen D Kolstad; Natalia Caporale; Meike Visel; Ryan R Klimczak; David V Schaffer; John G Flannery
Journal:  Mol Ther       Date:  2009-08-11       Impact factor: 11.454

7.  Gene Therapy for Leber Hereditary Optic Neuropathy: Initial Results.

Authors:  William J Feuer; Joyce C Schiffman; Janet L Davis; Vittorio Porciatti; Phillip Gonzalez; Rajeshwari D Koilkonda; Huijun Yuan; Anil Lalwani; Byron L Lam; John Guy
Journal:  Ophthalmology       Date:  2015-11-19       Impact factor: 12.079

8.  Intravitreal delivery of AAV-NDI1 provides functional benefit in a murine model of Leber hereditary optic neuropathy.

Authors:  Naomi Chadderton; Arpad Palfi; Sophia Millington-Ward; Oliverio Gobbo; Nora Overlack; Matthew Carrigan; Mary O'Reilly; Matthew Campbell; Carsten Ehrhardt; Uwe Wolfrum; Peter Humphries; Paul F Kenna; G Jane Farrar
Journal:  Eur J Hum Genet       Date:  2012-06-06       Impact factor: 4.246

9.  Restoring the ON Switch in Blind Retinas: Opto-mGluR6, a Next-Generation, Cell-Tailored Optogenetic Tool.

Authors:  Michiel van Wyk; Justyna Pielecka-Fortuna; Siegrid Löwel; Sonja Kleinlogel
Journal:  PLoS Biol       Date:  2015-05-07       Impact factor: 8.029

10.  Retinal gene therapy in patients with choroideremia: initial findings from a phase 1/2 clinical trial.

Authors:  Robert E MacLaren; Markus Groppe; Alun R Barnard; Charles L Cottriall; Tanya Tolmachova; Len Seymour; K Reed Clark; Matthew J During; Frans P M Cremers; Graeme C M Black; Andrew J Lotery; Susan M Downes; Andrew R Webster; Miguel C Seabra
Journal:  Lancet       Date:  2014-01-16       Impact factor: 79.321

View more
  39 in total

Review 1.  Applications of CRISPR/Cas9 in retinal degenerative diseases.

Authors:  Ying-Qian Peng; Luo-Sheng Tang; Shigeo Yoshida; Ye-Di Zhou
Journal:  Int J Ophthalmol       Date:  2017-04-18       Impact factor: 1.779

2.  Delivery of Adeno-Associated Virus Vectors in Adult Mammalian Inner-Ear Cell Subtypes Without Auditory Dysfunction.

Authors:  Yong Tao; Mingqian Huang; Yilai Shu; Adam Ruprecht; Hongyang Wang; Yong Tang; Luk H Vandenberghe; Qiuju Wang; Guangping Gao; Wei-Jia Kong; Zheng-Yi Chen
Journal:  Hum Gene Ther       Date:  2018-01-22       Impact factor: 5.695

Review 3.  Gene therapy development in hearing research in China.

Authors:  Zhen Zhang; Jiping Wang; Chunyan Li; Wenyue Xue; Yazhi Xing; Feng Liu
Journal:  Gene Ther       Date:  2020-07-17       Impact factor: 5.250

4.  Phenotypic characterization of P23H and S334ter rhodopsin transgenic rat models of inherited retinal degeneration.

Authors:  Matthew M LaVail; Shimpei Nishikawa; Roy H Steinberg; Muna I Naash; Jacque L Duncan; Nikolaus Trautmann; Michael T Matthes; Douglas Yasumura; Cathy Lau-Villacorta; Jeannie Chen; Ward M Peterson; Haidong Yang; John G Flannery
Journal:  Exp Eye Res       Date:  2017-11-06       Impact factor: 3.467

5.  Molecular Anatomy of the Developing Human Retina.

Authors:  Akina Hoshino; Rinki Ratnapriya; Matthew J Brooks; Vijender Chaitankar; Matthew S Wilken; Chi Zhang; Margaret R Starostik; Linn Gieser; Anna La Torre; Mario Nishio; Olivia Bates; Ashley Walton; Olivia Bermingham-McDonogh; Ian A Glass; Rachel O L Wong; Anand Swaroop; Thomas A Reh
Journal:  Dev Cell       Date:  2017-12-07       Impact factor: 12.270

6.  The primate model for understanding and restoring vision.

Authors:  Serge Picaud; Deniz Dalkara; Katia Marazova; Olivier Goureau; Botond Roska; José-Alain Sahel
Journal:  Proc Natl Acad Sci U S A       Date:  2019-12-23       Impact factor: 11.205

Review 7.  Novel therapeutics for Stargardt disease.

Authors:  Louise J Lu; Ji Liu; Ron A Adelman
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2017-03-11       Impact factor: 3.117

8.  The genetic architecture of Stargardt macular dystrophy (STGD1): a longitudinal 40-year study in a genetic isolate.

Authors:  Jane S Green; Darren D O'Rielly; Justin A Pater; Jim Houston; Hoda Rajabi; Dante Galutira; Tammy Benteau; Amy Sheaves; Nelly Abdelfatah; Donna Bautista; Jim Whelan; Terry-Lynn Young
Journal:  Eur J Hum Genet       Date:  2020-05-28       Impact factor: 4.246

9.  Visual Acuity Change Over 24 Months and Its Association With Foveal Phenotype and Genotype in Individuals With Stargardt Disease: ProgStar Study Report No. 10.

Authors:  Xiangrong Kong; Kaoru Fujinami; Rupert W Strauss; Beatriz Munoz; Sheila K West; Artur V Cideciyan; Michel Michaelides; Mohamed Ahmed; Ann-Margret Ervin; Etienne Schönbach; Janet K Cheetham; Hendrik P N Scholl
Journal:  JAMA Ophthalmol       Date:  2018-08-01       Impact factor: 7.389

10.  Gene Augmentation and Readthrough Rescue Channelopathy in an iPSC-RPE Model of Congenital Blindness.

Authors:  Pawan K Shahi; Dalton Hermans; Divya Sinha; Simran Brar; Hannah Moulton; Sabrina Stulo; Katarzyna D Borys; Elizabeth Capowski; De-Ann M Pillers; David M Gamm; Bikash R Pattnaik
Journal:  Am J Hum Genet       Date:  2019-01-24       Impact factor: 11.025

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.